The results of a new study comparing the efficacy of Isentress (raltegravir) and Sustiva (efavirenz) were presented on Sunday at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy.

Results of the study showed that the efficacy of Isentress was similar to the efficacy of Sustiva in treatment-naïve patients. Isentress reduced HIV RNA levels in two percent more patients than Sustiva, and, on average, Isentress raised CD4 levels higher. However, the RNA levels and CD4 counts were not statistically different between the patients receiving Isentress and the patients taking…

Description

Sustiva is a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) approved by the U.S. Food and Drug Administration for HIV-1-positive adults and children older than 3 years of age.  For patients beginning antiretroviral therapy for the first time, the U.S. Department of Health…